Health and Healthcare

Omrix Gets Acquired By J&J (OMRI, JNJ)

Jnj_logo_2It looks as though not quite all the mergers are dead on the medical tech and biotechnology front.  Johnson & Johnson (NYSE: JNJ) announced that it is acquiring Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI).  The $438 million cash tender offer will pay $25.00 per share to Omrix holders.

Omrix is a fully integrated biopharmaceutical company that develops andmarkets biosurgical and immunotherapy products.  It is expected tooperate as a stand-alone entity reporting through J&J’s ETHICON,Inc. unit, which is a provider of suture, mesh, hemostats and otherproducts for a wide range of surgical procedures.

The boards of directors of Johnson & Johnson and Omrix haveapproved the transaction. In addition, Robert Taub, Omrix’s Founder andChief Executive Officer, and entities controlled by Robert Taub, haveagreed to tender approximately 16% of Omrix’s outstanding shares in thetender offer.  J&J sees an after tax charge of roughly $120 millionand expects this deal to close by the end of 2008.

Omrix closed at $21.16 on Friday, and its 52-week trading range is $8.99 to $38.18.

Jon C. Ogg
November 24, 2008

In 20 Years, I Haven’t Seen A Cash Back Card This Good

After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers. 

A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.

Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous. 

 

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.